Low-dose aspirin for primary prevention of cardiovascular events in japanese patients 60 years or older with atherosclerotic risk factors: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 312, Issue 23, 2014, Pages 2510-2520

  Ikeda, Yasuo ^a   Shimada, Kazuyuki ^b   Teramoto, Tamio ^c   Uchiyama, Shinichiro ^d   Yamazaki, Tsutomu ^e   Oikawa, Shinichi ^f   Sugawara, Masahiro ^g   Ando, Katsuyuki ^h   Murata, Mitsuru ⁱ   Yokoyama, Kenji ^j   Ishizuka, Naoki ^k  

^a WASEDA UNIVERSITY   (Japan)

^b Shin Oyama City Hospital   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^e UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^f Japan Anti Tuberculosis Association   (Japan)

^g Sugawara Clinic   (Japan)

^h Kitamura Neurosurgery Clinic   (Japan)

ⁱ KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^k CANCER INSTITUTE HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGE; AGED; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EROSIVE GASTRITIS; EXTRACRANIAL HEMORRHAGE; FAMILY HISTORY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEARTBURN; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; JAPAN; JAPANESE (PEOPLE); LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SEX; SMOKING; STOMACH DISCOMFORT; STOMACH PAIN; SUBARACHNOID HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; BLEEDING; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; RISK FACTOR; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HEMORRHAGE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84919346036     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.15690     Document Type: Article

References (40)

1. World Health Organization. Atlas of heart disease and stroke. http://www.who.int/cardiovascular-diseases/resources/atlas/en/. Accessed May 29, 2014.
2. Hata J, Ninomiya T, Hirakawa Y, et al. Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961-2009). Circulation. 2013;128(11):1198-1205.
3. Ministry of Health Labour andWelfare Japan. Ministry of Health, Labour, andWelfare report: 2014 [in Japanese]. http://www.mhlw.go.jp/wp/hakusyo/kousei/14/. Accessed October 6, 2014.
4. Baigent C, Blackwell L, Collins R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborativemeta-analysis of individual participant data from randomized trials. Lancet. 2009;373(9678):1849-1860.
5. Bhatt DL, Steg PG, Ohman EM, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-189.
6. Yamazaki T, Goto S, Shigematsu H, et al; REACH Registry Investigators. Prevalence, awareness, and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J. 2007;71(7):995-1003.
7. Teramoto T, Shimada K, Uchiyama S, et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin vs no aspirin in patients with multiple risk factors for vascular events. Am Heart J. 2010;159(3):361- 369.e4.
8. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res. 2006;29(suppl):S1-S105.
9. Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases. http://www.researchgate .net/publication/246586151-1FS03-4-Japan-atherosclerosis-society-(JAS)-guidelines-for-diagnosis-and-treatment-of-atherosclerotic-cardiovascular-diseases. Accessed October 23, 2014.
10. The Japan Diabetes Society. Evidence-Based Practice Guideline for the Treatment of Diabetes in Japan [in Japanese]. Tokyo: Nankodo Co Ltd; 2004.
11. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res. 2006;29(suppl):S1-S105.
12. MatsumotoM, Nishimura T. Mersenne Twister: a 623-dimensionally equidistributed uniform psuedo-random number generator. http://diyhpl.us/-bryan/papers2/paperbot/Mersenne%20twister%3A%20a%20623 -dimensionally%20equidistributed%20uniform%20pseudo-random%20number%20generator.pdf. Accessed November 4, 2014.
13. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded End Point (PROBE) study: a novel design for intervention trials: Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1(2):113-119.
14. Luepker RV, Apple FS, Christenson RH, et al; AHA Council on Epidemiology and Prevention; AHA Statistics Committee;World Heart Federation Council on Epidemiology and Prevention; European Society of CardiologyWorking Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee;World Heart Federation Council on Epidemiology and Prevention; the European Society of CardiologyWorking Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108 (20):2543-2549.
15. Baba S; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001;54(3):191-201.
16. Ishii M, Goto Y. The Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients [in Japanese]. Junkankika. 2004;55:471-476.
17. Kyushu Lipid Intervention Study Group. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb. 2000;7 (2):110-121.
18. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111(2):383-390.
19. Matsuzaki M, Kita T, Mabuchi H, et al; J-LIT Study Group. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J. 2002;66(12):1087-1095.
20. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension. 1999;34(5):1129-1133.
21. Ogihara T; PATE-Hypertension Study Group in Japan. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens. 2000;13(5 pt 1):461-467.
22. Takishita S, Kawano Y, Omae T. Results of Japanese Trial on the Efficacy of Antihypertensive Treatment in the Elderly (JATE) and the Survey of Physician's Attitude to JATE and Large-Scaled Clinical Trials [in Japanese]. Rinshou-iyaku. 2000; 16:1363-1376.
23. Study Group on Long-term Antihypertensive Therapy. A 12-month comparison of ACE inhibitor and CA antagonist therapy inmild to moderate essential hypertension-the GLANT study. Hypertens Res. 1995;18(3):235-244.
24. Ogawa H, Nakayama M, Morimoto T, et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134-2141.
25. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
26. Fowkes FG, Price JF, Stewart MC, et al; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9): 841-848.
27. Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008;118(25):2702-2709.
28. Bartolucci AA, TenderaM, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107(12):1796-1801.
29. Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124(7):621-629.
30. Seshasai SR,Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209-216.
31. Shinohara Y, Katayama Y, Uchiyama S, et al; CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomized noninferiority trial. Lancet Neurol. 2010;9(10):959-968.
32. Yasue H, Ogawa H, Tanaka H, et al; Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Effects of aspirin and trapidil on cardiovascular events after acutemyocardial infarction. Am J Cardiol. 1999;83(9):1308-1313.
33. Yokoyama M, Origasa H, Matsuzaki M, et al; Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded end point analysis. Lancet. 2007;369(9567):1090-1098.
34. Cook NR, Lee IM, Zhang SM, MoorthyMV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159(2):77-85.
35. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of 5 randomized trials. Lancet. 2010;376(9754):1741-1750.
36. Ishikawa H, Mutoh M, Suzuki S, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumors in Asian patients: a randomized trial. Gut. 2014;63(11):1755-1759.
37. clinicaltrials.gov. A study to assess the efficacy and safety of enteric-coated acetylsalicylic acid in patients at moderate risk of cardiovascular disease (ARRIVE). https://clinicaltrials.gov/ct2/show/NCT00501059?term=ARRIVE+aspirin&rank=1. Accessed October 9, 2014.
38. clinicaltrials.gov. ASCEND: a study of cardiovascular events in diabetes. https://clinicaltrials.gov/ct2/show/NCT00135226?term=ascend+aspirin&rank=1. Accessed October 9, 2014.
39. clinicaltrials.gov. Aspirin in Reducing Events in the Elderly (ASPREE). https://clinicaltrials.gov/ct2/show/NCT01038583. Accessed October 9, 2014.
40. ISRCTN Register. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes. http://www.controlled-trials.com/isrctn48110081/48110081. Accessed October 9, 2014.